These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7698816)

  • 1. Twenty years into the saga of MHC-restriction.
    Ada G
    Immunol Cell Biol; 1994 Dec; 72(6):447-54. PubMed ID: 7698816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Disquisition on MHC Restriction and T Cell Recognition in Five Acts.
    Greenspan NS
    Viral Immunol; 2020 Apr; 33(3):153-159. PubMed ID: 32286186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ABC of Major Histocompatibility Complexes and T Cell Receptors in Health and Disease.
    Kedzierska K; Koutsakos M
    Viral Immunol; 2020 Apr; 33(3):160-178. PubMed ID: 32286182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legends of allergy/immunology: Rolf Zinkernagel and the co-discovery of MHC restriction together with Peter Doherty.
    Ludewig B
    Allergy; 2019 Jul; 74(7):1409-1411. PubMed ID: 30916402
    [No Abstract]   [Full Text] [Related]  

  • 5. Growth-dependent variation of major histocompatibility complex (MHC) restriction and expression of Ly-2 and CD3/alpha/beta T cell receptor in cloned cytotoxic T cells.
    Weltzien HU; Kempkes B; Studer R; Melchers I; Eichmann K
    Eur J Immunol; 1988 Mar; 18(3):431-7. PubMed ID: 2965649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Discovery of MHC restriction in antigen recognition of T cells].
    Lan GT; Zhu LP; Zhang W
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Oct; 24(5):539-41. PubMed ID: 12905783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC Restriction: Where Are We Now?
    Zareie P; Farenc C; La Gruta NL
    Viral Immunol; 2020 Apr; 33(3):179-187. PubMed ID: 32286180
    [No Abstract]   [Full Text] [Related]  

  • 8. The Nobel chronicles. 1996: Peter Charles Doherty (b 1940) and Rolf M Zinkernagel (b 1944).
    Raju TN
    Lancet; 2000 Jul; 356(9224):172. PubMed ID: 10963282
    [No Abstract]   [Full Text] [Related]  

  • 9. Rolf M. Zinkernagel--Felix Hoppe-Seyler Lecturer 1997.
    Hagmann M; Schaffner
    Biol Chem; 1997 Aug; 378(8):723-4. PubMed ID: 9377465
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the induction and expression of T cell-mediated immunity. XV. Role of non-MHC papain-sensitive target structures and Lyt-2 antigens in allogeneic and xenogeneic lectin-dependent cellular cytotoxicity (LDCC).
    Bonavida B; Katz J
    J Immunol; 1985 Sep; 135(3):1616-23. PubMed ID: 3874903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
    Lustgarten J; Waks T; Eshhar Z
    Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
    Muraoka S
    Eur J Immunol; 1991 Sep; 21(9):2095-103. PubMed ID: 1679712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.
    Herrmann T; Maryanski JL; Romero P; Fleischer B; MacDonald HR
    J Immunol; 1990 Feb; 144(4):1181-6. PubMed ID: 1968075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
    Tremblay N; Fontaine P; Perreault C
    Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the major histocompatibility complex in targeting effector T cells into a site of virus infection.
    Doherty PC; Allan JE
    Eur J Immunol; 1986 Oct; 16(10):1237-42. PubMed ID: 3490385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.
    Lanier LL; Le AM; Cwirla S; Federspiel N; Phillips JH
    Fed Proc; 1986 Nov; 45(12):2823-8. PubMed ID: 3095151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G; Malorni W; Donelli G
    Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making the connection: antibody responsiveness and MHC genes.
    Bennink JR
    J Immunol; 2004 Aug; 173(3):1499. PubMed ID: 15265874
    [No Abstract]   [Full Text] [Related]  

  • 20. Infection of cultured murine brain cells by Semliki Forest virus: effects of interferon-alpha beta on viral replication, viral antigen display, major histocompatibility complex antigen display and lysis by cytotoxic T lymphocytes.
    Morris A; Tomkins PT; Maudsley DJ; Blackman M
    J Gen Virol; 1987 Jan; 68 ( Pt 1)():99-106. PubMed ID: 3492589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.